Previous close | 33.64 |
Open | 33.02 |
Bid | 32.63 x 50000 |
Ask | 33.61 x 50000 |
Day's range | 33.00 - 33.02 |
52-week range | 22.35 - 34.48 |
Volume | |
Avg. volume | 204 |
Market cap | 64.234B |
Beta (5Y monthly) | 0.29 |
PE ratio (TTM) | 54.10 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.36 (1.08%) |
Ex-dividend date | 27 Sept 2024 |
1y target est | N/A |
AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.
Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.